At Investor Conferences

Advertisement

Picture [iito] Männer Ballett 650x80px
Organisation › Details

Sangamo Therapeutics Inc. (Nasdaq: SGMO)

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in Phase 2 clinical trials for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF™) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN™) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. *

 

Period Start 2018-07-23 renamed before
  Group Sangamo (Group)
  Predecessor Sangamo BioSciences Inc. (Nasdaq: SGMO)
Product Industry BIOTECH
Person Person Macrae, Sandy (Sangamo 201807 CEO)
     
  City n. a. 
    Address record changed: 2018-07-23
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2020-07-08

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Sangamo (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top